Altimmune Inc (ALT) volume exceeds 4.5 million: A new investment opportunity for investors

Zack King

On Monday, Altimmune Inc (NASDAQ: ALT) was -4.66% drop from the session before settling in for the closing price of $3.86. A 52-week range for ALT has been $2.90 – $8.03.

A company in the Healthcare sector has jumped its sales by 3.48% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 27.05%. With a float of $103.61 million, this company’s outstanding shares have now reached $104.34 million.

Altimmune Inc (ALT) Insider Updates

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Altimmune Inc stocks. The insider ownership of Altimmune Inc is 0.71%, while institutional ownership is 40.02%. The most recent insider transaction that took place on Dec 29 ’25, was worth 2,003. In this transaction Director of this company bought 527 shares at a rate of $3.80, taking the stock ownership to the 527 shares. Before that another transaction happened on Dec 23 ’25, when Company’s Director bought 12,500 for $4.10, making the entire transaction worth $51,250. This insider now owns 12,500 shares in total.

Altimmune Inc (ALT) Performance Highlights and Predictions

Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.33 earnings per share (EPS) during the time that was better than consensus figure (set at -0.34) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 27.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.04% during the next five years compared to 3.48% growth over the previous five years of trading.

Altimmune Inc (NASDAQ: ALT) Trading Performance Indicators

You can see what Altimmune Inc (ALT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 17.18. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 19198.92.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.07, a number that is poised to hit -0.24 in the next quarter and is forecasted to reach -1.24 in one year’s time.

Technical Analysis of Altimmune Inc (ALT)

Let’s dig in a bit further. During the last 5-days, its volume was 4.17 million. That was better than the volume of 3.6 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 3.45%.

During the past 100 days, Altimmune Inc’s (ALT) raw stochastic average was set at 12.80%, which indicates a significant increase from 1.26% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.36 in the past 14 days, which was higher than the 0.24 volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $4.49, while its 200-day Moving Average is $4.61. However, in the short run, Altimmune Inc’s stock first resistance to watch stands at $3.80. Second resistance stands at $3.91. The third major resistance level sits at $3.99. If the price goes on to break the first support level at $3.61, it is likely to go to the next support level at $3.53. Assuming the price breaks the second support level, the third support level stands at $3.42.

Altimmune Inc (NASDAQ: ALT) Key Stats

There are 104,342K outstanding shares of the company, which has a market capitalization of 383.98 million. As of now, sales total 20 K while income totals -95,060 K. Its latest quarter income was 10 K while its last quarter net income were -19,010 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.